Anti-CD14 Antibody, PE-Labeled
This anti-CD14 antibody is a purified recombinant antibody, which is labeled with R-Phycoerythrin (PE). This antibody has been tested by flow cytometry for specific binding to human CD14 on the surface of CD14 CHO Recombinant Cell Line (BPS Bioscience #78335).
≥90%
Aqueous buffer solution.
8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, 0.09% Sodium Azide, 0.2% BSA, and up to 20% glycerol. May contain a protein stabilizer.
PE is an oligomeric protein complex (270 kDa) from red algae that exhibits intensely bright red-orange fluorescence with excitation peak at 566 nm and an emission peak at 574 nm. The complex consists of six heterodimers, α subunit (18 kDa) and β-subunit (20 kDa), and an additional γ-subunit (34 kDa).
CD14 (Cluster of Differentiation-14) is a surface antigen expressed predominantly by monocytes and macrophages. It is considered a patterned recognition receptor (PRR), which recognizes pathogen markers. Specifically, CD14 acts as a co-receptor for lipopolysaccharides (LPS) found in the outer membrane of gram-negative bacteria. Through this interaction, CD14 supports initiation of the innate immune response during bacterial infection. CD14 also contributes toward immune responses to viral pathogens such as human respiratory syncytial virus (RSV), and may amplify the inflammatory response observed in severe cases of SARS-CoV-2 infection (COVID-19). Monoclonal antibodies against CD14 are currently undergoing clinical trial as a candidate treatment to limit severe inflammatory responses common in patients hospitalized with COVID-19.